Table 5.
The interaction between gene promoter region methylation and different cancer stages for 5-year TTP of CRC patients.
| Normal tissues | Tumor tissues | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of subjects | No. of cases (%) | Crude | Adjusted | No. of subjects | No. of cases (%) | Crude | Adjusted | |||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||||
| ≧2 of genes | ||||||||||||
| UnMe/local (1&2) | 36 | 6 (16.7) | 1.00 | Referent | 1.00 | Referent | 20 | 4 (20.0) | 1.00 | Referent | 1.00 | Referent |
| UnMe/advanced (3&4) | 31 | 16 (51.6) | 3.49 | (1.21 to 10.1) | 6.30 | (1.39 to 28.6) | 8 | 3 (37.5) | 2.50 | (0.50 to 12.4) | 7.36 | (0.76 to 71.7) |
| Me/local (1&2) | 41 | 3 (7.3) | 0.19 | (0.02 to 1.60) | 0.32 | (0.03 to 3.74) | 57 | 5 (8.8) | 0.34 | (0.07 to 1.69) | 0.51 | (0.04 to 5.82) |
| Me/advanced (3&4) | 45 | 38 (84.4) | 9.76 | (3.78 to 25.3) | 15.0 | (3.52 to 63.6) | 68 | 51 (75.0) | 6.47 | (2.00 to 21.0) | 11.5 | (1.56 to 85.2) |
| p for trend | <0.01 | <0.01 | <0.01 | <0.01 | ||||||||
Abbreviations: TTP, time to progression; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.
Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade and tumor location.
UnMe/loccal (1&2): gene promoter region unmethylated with cancer stage 1 or 2.
UnMe/advanced (3&4): gene promoter region unmethylated with cancer stage 3 or 4.
Me/local (1&2): gene promoter region methylated with cancer stage 1 or 2.
Me/advanced (3&4): gene promoter region methylated with cancer stage 3 or 4.